As for the comparison of oral semaglutide with other oral agents, in the PIONEER 2 open-label trial, oral semaglutide (14 mg once daily) was evaluated against the sodium-glucose co-transporter 2 inhibitor (SGLT2i) empagliflozin (25 mg once daily) for 52 weeks in 822 patients with T2D uncontrolled on metformin with a mean HbA1c level of 8.1%
Hair shedding linked to GLP-1 medications is usually telogen effluvium, a temporary type of hair loss triggered by rapid weight loss
It's crucial to consult with a healthcare provider to determine the approach that is most suitable for you
Side effects included nausea (44%), vomiting (24%), diarrhea (30%), constipation (24%), abdominal pain (20%), headache (14%), fatigue (11%), dizziness (8%), abdominal distension (7%), and belching (7%)
Both drugs exhibit similar side effect profiles